A macrolide from Streptomyces sp. modulates apoptosis and autophagy through Mcl-1 downregulation in human breast cancer cells

Environ Toxicol. 2021 Jul;36(7):1316-1325. doi: 10.1002/tox.23128. Epub 2021 Mar 13.

Abstract

Secondary metabolites in marine organisms exhibit various pharmacological activities against diseases, such as cancer. In this study, the anti-proliferative effect of JBIR-100, a macrolide isolated from Streptomyces sp., was investigated in breast cancer cells. Cell growth was inhibited in response to JBIR-100 treatment concentration- and time-dependently in both MCF-7 and MDA-MB-231 breast cancer cells. JBIR-100 caused apoptosis, as verified by caspase activation and the cleavage of PARP. Western blotting revealed that JBIR-100 modulated the expression of Akt/NF-κB signaling components and Bcl-2 family members. Overexpression of Mcl-1 partially rescued MCF-7 cells from JBIR-100-induced cytotoxicity. In addition, transmission electron microscopy analyses, confocal analysis, and western blot assay indicated that JBIR-100 inhibited autophagy in MCF-7 cells. Exposure to the autophagy inhibitor did not synergize JBIR-100-induced apoptosis. In summary, our results suggested that JBIR-100 may be potentially used for breast cancer therapy.

Keywords: JBIR-100; apoptosis; autophagy; macrolide; mcl-1.

MeSH terms

  • Apoptosis
  • Autophagy
  • Breast Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Cell Proliferation
  • Down-Regulation
  • Humans
  • MCF-7 Cells
  • Macrolides / pharmacology
  • Streptomyces*

Substances

  • Macrolides